Novo Nordisk Levemir To Launch Within Next 12 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-acting insulin analogue clears FDA June 17 for treatment of type 1 and type 2 diabetes. Firm says approval makes it the only company in U.S. with a "full range" of short-acting and long-acting insulin analogues.
You may also be interested in...
Novo Nordisk Declares Levemir A Winner In U.S. Market
Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.
Novo Nordisk Declares Levemir A Winner In U.S. Market
Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.
Novo Nordisk Emphasizes Levemir “Predictability”
Planned second quarter launch would be nearly one year after FDA approval.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: